Pharmaceutical Technology

OCTOBER 6, 2022

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . This trial will evaluate the safety of the vaccine and generate efficacy data.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

pharmaphorum

OCTOBER 5, 2022

Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium. At the moment most cases are treated with azithromycin, with intravenous ceftriaxone generally reserved as a last-line therapy.

Vaccination 98

Vaccination Vaccine Immune Response Bacterium 98

XTalks

NOVEMBER 10, 2020

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. While Merck’s previous shot, Pneumovax 23, defends against 23 serotypes and has been on the market for almost four decades, the immune responses it generates are not as durable as Prevnar 13.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. VAX-24 met standard superiority criteria for four additional serotypes, as stated in the October 24 press release.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162